New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
复制标题
导致颌骨坏死的新型非双膦酸盐药物。
DOI：
10.3290/j.ohpd.a34055
复制
发表时间：
2015
影响因子：
1.6
通讯作者：
G. Hernández
中科院分区：
文献类型：
--
作者：
Lucía Ramírez;R. López‐Pintor;E. Casañas;L. Arriba;G. Hernández
目的
本文的目的是回顾目前非双膦酸类抗癌药物Denosumab、Bevacizumab和Sunitinib(与双磷酸盐[BP]合用或不合用)与患者颌骨坏死(ONJ)之间的关系。
材料和方法
使用关键词颌骨坏死、口服双磷酸盐、Denosumab、Bevacizumab和Sunitinib进行文献综述。获得了报告的与使用Denosumab、Bevacizumab和Sunitinib有关的ONJ病例的文章。
结果
文献表明，Denosumab可引起与微创或拔牙等触发因素相关的ONJ。该药物与唑来膦酸联合使用可能具有协同作用。贝伐单抗可引起ONJ；然而，关于其与BP的协同作用存在很大争议。孙尼替尼会导致ONJ，与BP一起可能会增加发生病变的风险。
结论
Denosumab、Sunitinib或Bevacizumab是ONJ发生的原因。与BP单独治疗相比，这些因素和BP的任何一种组合都可能增加发生ONJ的风险。
PURPOSE
The aim of this paper was to review the current literature associating the non-bisphosphonate cancer-treatment drugs Denosumab, Bevacizumab and Sunitinib (used with or without bisphosphonate [BP]) with the presence of osteonecrosis of the jaws (ONJ) in patients.
MATERIALS AND METHODS
A literature review was conducted using the keywords osteonecrosis of the jaws, oral biphosphosnates, Denosumab, Bevacizumab and Sunitinib. Articles were obtained that reported cases of ONJ associated with the use of Denosumab, Bevacizumab and Sunitinib.
RESULTS
The literature shows that Denosumab can cause ONJ associated with triggers such as microtraumas or dental extractions. The combination of the drug along with zoledronic acid may have a synergistic effect. Bevacizumab may cause ONJ; however, there is much controversy regarding its synergistic action when used with BP. Sunitinib causes ONJ, and together with BP could increase the risk of developing lesions.
CONCLUSION
Denosumab, Sunitinib or Bevacizumab are causal agents in the development of ONJ. The combination of any of these along with BPs could increase the risk of developing ONJ over that posed by BP treatment alone.